Cozzi Emanuele, Colpo Anna, De Silvestro Giustina
Department of Cardiac, Thoracic and Vascular Sciences, Transplant Immunology Unit, Padua University Hospital, Padova, Italy; CORIT (Consortium for Research in Organ Transplantation), Padova, Italy.
Department of Transfusion Medicine, Padua University Hospital, Padova, Italy.
Transfus Apher Sci. 2017 Aug;56(4):498-505. doi: 10.1016/j.transci.2017.07.005. Epub 2017 Jul 8.
Organ transplantation represents the preferred treatment option for many patients in terminal organ failure. The half-life of transplanted organs, however, is still far from being satisfactory with the vast majority of the organs failing within the first two decades following transplantation. At this stage, it has become apparent that rejection (prevalently mediated by humoral events) remains the primary cause of graft loss after the first year. In this light, studies are underway to better comprehend the immune events underlying graft rejection and novel immunosuppressive strategies are being explored. In this context, therapeutic apheresis techniques, that include therapeutic plasma exchange (TPE), immunoadsorption (IA) and extracorporeal photochemotherapy (ECP), represent an important adjunct in the current immunosuppressive armamentarium. This article briefly reviews our current understanding of the immune process underlying rejection of a solid organ transplant and describes the principal areas of application of therapeutic apheresis techniques in transplantation.
器官移植是许多终末期器官衰竭患者的首选治疗方案。然而,移植器官的半衰期仍远不尽人意,绝大多数器官在移植后的头二十年里就会失效。在这个阶段,很明显,排斥反应(主要由体液事件介导)仍然是移植后第一年移植物丢失的主要原因。有鉴于此,正在开展研究以更好地理解移植物排斥反应背后的免疫事件,并探索新的免疫抑制策略。在这种背景下,治疗性血液成分单采技术,包括治疗性血浆置换(TPE)、免疫吸附(IA)和体外光化学疗法(ECP),是当前免疫抑制手段中的一项重要辅助措施。本文简要回顾了我们目前对实体器官移植排斥反应背后免疫过程的理解,并描述了治疗性血液成分单采技术在移植中的主要应用领域。